Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cowan

Showing results (931-940 of 1,002) with videos related to

Pageof 101
Sort By:
Blood|May 6, 2018
B-cell differentiation and IL-21 response in <i>IL2RG/JAK3</i> SCID patients after hematopoietic stem cell transplantationAlexandra M Miggelbrink, Brent R Logan, Rebecca H Buckley, et al.
Transplantation and Cellular Therapy|September 10, 2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 TrialsAndrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.
JAMA Oncology|May 26, 2018
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016Andrew J Cowan, Christine Allen, Aleksandra Barac, et al.
Blood|June 1, 1996
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndromeC Peters, M Balthazor, E G Shapiro, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2017
Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research ReportPooja Khandelwal, Heather R Millard, Elizabeth Thiel, et al.
Mabs|March 29, 2012
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administrationYanan Zheng, Devin B Tesar, Lisa Benincosa, et al.
Blood|June 11, 2011
Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative studyDaniele Moratto, Silvia Giliani, Carmem Bonfim, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2001
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitutionD L Musso, M W Andersen, R C Andrews, et al.
Pageof 101

Showing results (931-940 of 1,002) with videos related to

Sort By:
Pageof 101
Blood|May 6, 2018
B-cell differentiation and IL-21 response in <i>IL2RG/JAK3</i> SCID patients after hematopoietic stem cell transplantationAlexandra M Miggelbrink, Brent R Logan, Rebecca H Buckley, et al.
Transplantation and Cellular Therapy|September 10, 2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 TrialsAndrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.
JAMA Oncology|May 26, 2018
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016Andrew J Cowan, Christine Allen, Aleksandra Barac, et al.
Blood|June 1, 1996
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndromeC Peters, M Balthazor, E G Shapiro, et al.
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2017
Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research ReportPooja Khandelwal, Heather R Millard, Elizabeth Thiel, et al.
Mabs|March 29, 2012
Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administrationYanan Zheng, Devin B Tesar, Lisa Benincosa, et al.
Blood|June 11, 2011
Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative studyDaniele Moratto, Silvia Giliani, Carmem Bonfim, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2001
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitutionD L Musso, M W Andersen, R C Andrews, et al.
Pageof 101